TABLE 1.

Baseline demographics

Characteristica	Value for group		P value
	Pre-BC-GP (n = 65)	Post-BC-GP (n = 74)
Age [mean (SD)]	54.5 (22.0)	57.3 (20.8)	0.43
No. (%) with malignancy	27 (41.5)	32 (43.2)	0.84
Solid organ tumor	14 (21.5)	21 (28.4)	0.35
Hematologic malignancy	14 (21.5)	14 (18.9)	0.70
HSCT	8 (12.3)	3 (4.1)	0.07
No. (%) with solid organ transplant recipient	2 (3.1)	4 (5.4)	0.50
No. (%) diabetic	17 (26.2)	28 (37.8)	0.14
No. (%) HIV positive	1 (1.5)	2 (2.7)	0.64
No. (%) with recent surgery within 1 mo	12 (18.5)	11 (14.9)	0.57
No. (%) with systemic steroids	8 (12.3)	10 (13.5)	0.83
No. (%) with immunomodulating agentsb	13 (20.0)	13 (17.6)	0.71
No. (%) with dialysis	6 (9.2)	6 (8.1)	0.81
No. (%) neutropenic (ANC < 0.5)	13 (20.0)	11 (14.9)	0.42
Mean (SD) ANC for neutropenic patients	0.08 (0.19)	0.13 (0.18)
No. (%) with renal failure (serum creatinine > 2)	17 (26.2)	16 (21.6)	0.53
No. (%) with hepatic failure	9 (13.9)	6 (8.1)	0.28
No. (%) in intensive care unit	6 (9.2)	10 (13.5)	0.43
No. (%) with TPN	6 (9.2)	3 (4.1)	0.22
No. (%) with endocarditis proven by ECHO	4 (8.9)	9 (18.0)	0.20
No. (%) with central catheter	28 (43.1)	26 (35.1)	0.34

^aHSCT, hematopoietic stem cell transplant; TPN, total parenteral nutrition.

^bImmunomodulating agents include tacrolimus, mycophenolate, cyclosporine, azathioprine, sirolimus, or other transplant biologics.